Osteopontin in systemic sclerosis and its role in dermal fibrosis

Journal of Investigative Dermatology

Volumn 132, Issue 6, 2012, Pages 1605-1614

  Wu, Minghua ^a   Schneider, Daniel J ^a   Mayes, Maureen D ^a   Assassi, Shervin ^a   Arnett, Frank C ^a   Tan, Filemon K ^a   Blackburn, Michael R ^a   Agarwal, Sandeep K ^a,b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; OSTEOPONTIN; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; IMMUNOHISTOLOGY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY CELL; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MOUSE; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SKIN DEFECT; SKIN FIBROSIS; SYSTEMIC SCLEROSIS;

EID: 84861182154     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2012.32     Document Type: Article

References (58)

1. Abraham DJ, Varga J (2005) Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol 26:587-95 (Pubitemid 41726446)
2. Agarwal SK, Wu M, Livingston CK et al. (2011) Toll-like receptor 3 upregulation by type I interferon in healthy and scleroderma dermal fibroblasts. Arthritis Res Ther 13:R3
3. Anborgh PH, Mutrie JC, Tuck AB et al. (2011) Pre- and post-translational regulation of osteopontin in cancer. J Cell Commun Signal 5:111-22
4. Arnett FC (2006) Is scleroderma an autoantibody mediated disease? Curr Opin Rheumatol 18:579-81 (Pubitemid 44607409)
5. Ashkar S, Weber GF, Panoutsakopoulou V et al. (2000) Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 287:860-4 (Pubitemid 30084330)
6. Berman JS, Serlin D, Li X et al. (2004) Altered bleomycin-induced lung fibrosis in osteopontin-deficient mice. Am J Physiol Lung Cell Mol Physiol 286:L1311-L8
7. Brigstock DR, Goldschmeding R, Katsube KI et al. (2003) Proposal for a unified CCN nomenclature. Mol Pathol 56:127-8 (Pubitemid 36461474)
8. Chang PL, Harkins L, Hsieh YH et al. (2008) Osteopontin expression in normal skin and non-melanoma skin tumors. J Histochem Cytochem 56:57-66 (Pubitemid 350276502)
9. Charles C, Clements P, Furst DE (2006) Systemic sclerosis: hypothesis-driven treatment strategies. Lancet 367:1683-91 (Pubitemid 43728250)
10. Chen Y, Shi-wen X, van Beek J et al. (2005) Matrix contraction by dermal fibroblasts requires transforming growth factor-beta/activin-linked kinase 5, heparan sulfate-containing proteoglycans, and MEK/ERK: insights into pathological scarring in chronic fibrotic disease. Am J Pathol 167:1699-711 (Pubitemid 41713321)
11. Desai B, Rogers MJ, Chellaiah MA (2007) Mechanisms of osteopontin and CD44 as metastatic principles in prostate cancer cells. Mol Cancer 6:18
12. Desmouliere A, Chaponnier C, Gabbiani G (2005) Tissue repair, contraction, and the myofibroblast. Wound Repair Regen 13:7-12 (Pubitemid 40250424)
13. Douglas HE (2010) TGF-ss in wound healing: a review. J Wound Care 19:403-6
14. Fleischmajer R, Perlish JS, Reeves JR (1977) Cellular infiltrates in scleroderma skin. Arthritis Rheum 20:975-84
15. Fujii H, Shimada Y, Hasegawa M et al. (2004) Serum levels of a Th1 chemoattractant IP-10 and Th2 chemoattractants, TARC and MDC, are elevated in patients with systemic sclerosis. J Dermatol Sci 35:43-51 (Pubitemid 38759740)
16. Gabbiani G (1992) The biology of the myofibroblast. Kidney Int 41:530-2
17. Gabbiani G (2003) The myofibroblast in wound healing and fibrocontractive diseases. J Pathol 200:500-3 (Pubitemid 36818250)
18. Gardner H, Shearstone JR, Bandaru R et al. (2006) Gene profiling of scleroderma skin reveals robust signatures of disease that are imperfectly reflected in the transcript profiles of explanted fibroblasts. Arthritis Rheum 54:1961-73 (Pubitemid 43877946)
19. Gourh P, Arnett FC, Assassi S et al. (2009) Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations. Arthritis Res Ther 11:R147
20. Higley H, Persichitte K, Chu S et al. (1994) Immunocytochemical localization and serologic detection of transforming growth factor beta 1. Association with type I procollagen and inflammatory cell markers in diffuse and limited systemic sclerosis, morphea, and Raynaud's phenomenon. Arthritis Rheum 37:278-88
21. Hinz B (2007) Formation and function of the myofibroblast during tissue repair. J Invest Dermatol 127:526-37
22. Huang W, Zhu G, Huang M et al. (2010) Plasma osteopontin concentration correlates with the severity of hepatic fibrosis and inflammation in HCVinfected subjects. Clin Chim Acta 411:675-8
23. Kissin EY, Merkel PA, Lafyatis R (2006) Myofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosis. Arthritis Rheum 54:3655-60 (Pubitemid 44737178)
24. Kohan M, Breuer R, Berkman N (2009) Osteopontin induces airway remodeling and lung fibroblast activation in a murine model of asthma. Am J Respir Cell Mol Biol 41:290-6
25. Leask A, Sa S, Holmes A et al. (2001) The control of ccn2 (ctgf) gene expression in normal and scleroderma fibroblasts. Mol Pathol 54:180-3 (Pubitemid 32539611)
26. Lenga Y, Koh A, Perera AS et al. (2008) Osteopontin expression is required for myofibroblast differentiation. Circ Res 102:319-27 (Pubitemid 351271652)
27. LeRoy EC, Black C, Fleischmajer R et al. (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202-5 (Pubitemid 18073738)
28. Liaw L, Birk DE, Ballas CB et al. (1998) Altered wound healing in mice lacking a functional osteopontin gene (spp1). J Clin Invest 101:1468-78 (Pubitemid 28166845)
29. Lorenzen JM, Kramer R, Meier M et al. (2010) Osteopontin in the development of systemic sclerosis-relation to disease activity and organ manifestation. Rheumatology (Oxford) 49:1989-91
30. Matsui Y, Jia N, Okamoto H et al. (2004) Role of osteopontin in cardiac fibrosis and remodeling in angiotensin II-induced cardiac hypertrophy. Hypertension 43:1195-201 (Pubitemid 38691740)
31. Mori R, Shaw TJ, Martin P (2008) Molecular mechanisms linking wound inflammation and fibrosis: knockdown of osteopontin leads to rapid repair and reduced scarring. J Exp Med 205:43-51 (Pubitemid 351185714)
32. O'Kane S, Ferguson MW (1997) Transforming growth factor beta s and wound healing. Int J Biochem Cell Biol 29:63-78 (Pubitemid 27096420)
33. O'Regan A (2003) The role of osteopontin in lung disease. Cytokine Growth Factor Rev 14:479-88
34. Pardo A, Gibson K, Cisneros J et al. (2005) Up-regulation and profibrotic role of osteopontin in human idiopathic pulmonary fibrosis. PLoS Med 2:e251
35. Prasse A, Stahl M, Schulz G et al. (2009) Essential role of osteopontin in smoking-related interstitial lung diseases. Am J Pathol 174:1683-91
36. Rangaswami H, Kundu GC (2007) Osteopontin stimulates melanoma growth and lung metastasis through NIK/MEKK1-dependent MMP-9 activation pathways. Oncol Rep 18:909-15
37. Reveille JD, Fischbach M, McNearney T et al. (2001) Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. Semin Arthritis Rheum 30:332-46 (Pubitemid 32298859)
38. Rittling SR (2011) Osteopontin in macrophage function. Exp Rev Mol Med 13:e15
39. Sargent JL, Milano A, Bhattacharyya S et al. (2010) A TGFbeta-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity. J Invest Dermatol 130:694-705
40. Schneider DJ, Lindsay JC, Zhou Y et al. (2010) Adenosine and osteopontin contribute to the development of chronic obstructive pulmonary disease. FASEB J 24:70-80
41. Sharma A, Singh AK, Warren J et al. (2006) Differential regulation of angiogenic genes in diabetic wound healing. J Invest Dermatol 126:2323-31 (Pubitemid 44413181)
42. Shinohara ML, Lu L, Bu J et al. (2006) Osteopontin expression is essential for interferon-alpha production by plasmacytoid dendritic cells. Nat Immunol 7:498-506
43. Takagawa S, Lakos G, Mori Y et al. (2003) Sustained activation of fibroblast transforming growth factor-beta/Smad signaling in a murine model of scleroderma. J Invest Dermatol 121:41-50 (Pubitemid 36900453)
44. Takahashi F, Takahashi K, Okazaki T et al. (2001) Role of osteopontin in the pathogenesis of bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 24:264-71 (Pubitemid 32228374)
45. Tan FK, Zhou X, Mayes MD et al. (2006) Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. Rheumatology (Oxford) 45:694-702 (Pubitemid 43985337)
46. Tomasek JJ, Gabbiani G, Hinz B et al. (2002) Myofibroblasts and mechanoregulation of connective tissue remodelling.Nat RevMol Cell Biol 3:349-63 (Pubitemid 34619269)
47. Trueblood NA, Xie Z, Communal C et al. (2001) Exaggerated left ventricular dilation and reduced collagen deposition after myocardial infarction in mice lacking osteopontin. Circ Res 88:1080-7 (Pubitemid 34137122)
48. Valentini G, Baroni A, Esposito K et al. (2001) Peripheral blood T lymphocytes from systemic sclerosis patients show both Th1 and Th2 activation. J Clin Immunol 21:210-7 (Pubitemid 32434308)
49. Varga J, Abraham D (2007) Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 117:557-67 (Pubitemid 46348510)
50. Varga J, Whitfield ML (2009) Transforming growth factor-beta in systemic sclerosis (scleroderma). Front Biosci (ScholEd) 1:226-35
51. Vetrone SA, Montecino-Rodriguez E, Kudryashova E et al. (2009) Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-beta. J Clin Invest 119:1583-94
52. Wang KX, Denhardt DT (2008) Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev 19:333-45
53. Wu M, Melichian DS, de la GM et al. (2009) Essential roles for early growth response transcription factor Egr-1 in tissue fibrosis and wound healing. Am J Pathol 175:1041-55
54. Wynn TA (2007) Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest 117:524-9 (Pubitemid 46348506)
55. Yamamoto T (2002) Animal model of sclerotic skin induced by bleomycin: a clue to the pathogenesis of and therapy for scleroderma? Clin Immunol 102:209-16 (Pubitemid 34259254)
56. Yamamoto T, Nishioka K (2002) Animal model of sclerotic skin. V: Increased expression of alpha-smooth muscle actin in fibroblastic cells in bleomycin-induced scleroderma. Clin Immunol 102:77-83
57. Yamamoto T, Nishioka K (2005) Cellular and molecular mechanisms of bleomycin-induced murine scleroderma: current update and future perspective. Exp Dermatol 14:81-95 (Pubitemid 40277574)
58. Zheng W, Li R, Pan H et al. (2009) Role of osteopontin in induction of monocyte chemoattractant protein 1 and macrophage inflammatory protein 1beta through the NF-kappaB and MAPK pathways in rheumatoid arthritis. Arthritis Rheum 60:1957-65